Skip to main content
. Author manuscript; available in PMC: 2019 Nov 27.
Published in final edited form as: Environ Mol Mutagen. 2019 Feb 27;60(6):513–533. doi: 10.1002/em.22274

Fig. 7.

Fig. 7.

Left panel: BMD analyses of clastogen compounds represented in cross system plots with BMD50 CIs for in vitro MN vs. BMD50 CIs 24 hr γH2AX responses in TK6 cells, with both x and y axes representing Log10 concentration of compounds in μM. The dashed parallel lines are drawn in such a way that encompasses all of the CIs. Dashed square box represents default PROAST output encompassing finite BMD CIs. Right panel: BMD50 CIs for in vitro MN vs. BMD50 24 hr p53 responses in TK6 cells, with both x and y axes representing Log10 concentration of compounds in μM. Dashed parallel lines encompass most of the BMD CIs. Dashed square box represents default PROAST output encompassing finite BMD CIs except outliers. Compound ola lies outside the general observed trend, with an unbound upper CI in the p53 endpoint. Compound cis displays an unbound upper CI in the p53 endpoint. See Table I for compound abbreviations (BMD, Benchmark Dose; CI, confidence interval; MN, micronucleus).